Advertisement

Cholesterol mass efflux capacity and coronary artery calcium: The multi-ethnic study of atherosclerosis

Published:September 13, 2022DOI:https://doi.org/10.1016/j.jacl.2022.09.004

      Highlights

      • CMEC quantifies net movement of cholesterol between cells and HDL.
      • We determined the association of CMEC with CAC.
      • Higher CMEC levels were not associated with lower CAC score or higher CAC density.
      • CV risk associated with HDL CMEC appears unrelated to calcified plaque burden.

      Abstract

      We assessed the cross-sectional and longitudinal relationships of high-density lipoprotein (HDL)-mediated cholesterol mass efflux capacity (CMEC) with coronary artery calcium (CAC) score and CAC density. CMEC was measured in 1626 Multi-Ethnic Study of Atherosclerosis (MESA) participants in samples obtained between 2000 and 2002 as part of two nested case-control studies, one with cases of incident cardiovascular disease and the other with cases of carotid plaque progression by ultrasound. Cardiac CT examinations for the presence of CAC were performed at baseline and at two additional examinations. CAC scores (Agatston and volume) and density scores (for those with positive CAC) were calculated. Multivariable linear regression modeling per SD increment of CMEC was used to estimate the associations of CMEC with each of these CAC measures. We found no association between higher CMEC and either lower CAC scores or a higher CAC density. We also found no association between higher CMEC and progression of any of these CAC measures. These findings suggest that HDL-mediated cholesterol efflux may be associated with cardiovascular risk via mechanisms unrelated to burden of calcified plaque.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boden W.E.
        • Probstfield J.L.
        • Anderson T.
        • Chaitman B.R.
        • Desvignes-Nickens P.
        • Koprowicz K.
        • McBride R.
        • Teo K.
        • Weintraub W.
        • AIM-HIGH Investigators
        Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
        N Engl J Med. 2011; 365: 2255-2267
        • Schwartz G.G.
        • Olsson A.G.
        • Abt M.
        • Ballantyne C.M.
        • Barter P.J.
        • Brumm J.
        • Chaitman B.R.
        • Holme I.M.
        • Kallend D.
        • Leiter L.A.
        • et al.
        dal-OUTCOMES investigators: effects of dalcetrapib in patients with a recent acute coronary syndrome.
        N Engl J Med. 2012; 367: 2089-2099
        • Tall A.R.
        Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins.
        J Intern Med. 2008; 263: 256-273
        • Rohatgi A.
        • Khera A.
        • Berry J.D.
        • et al.
        HDL cholesterol efflux capacity and incident cardiovascular events.
        N Engl J Med. 2014; 371: 2383-2393
        • Shea S.
        • Stein J.H.
        • Jorgenson N.W.
        • McClelland R.L.
        • Tascau L.
        • Shrager S.
        • et al.
        Cholesterol mass efflux capacity, incident cardiovascular disease, and progression of carotid plaque: the multi-ethnic study of atherosclerosis.
        Arterioscler Thromb Vasc Biol. 2019; 39: 89-96
        • Ormseth M.J.
        • Yancey P.G.
        • Yamamoto S.
        • Oeser A.M.
        • Gebretsadik T.
        • Shintani A.
        • et al.
        Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis.
        IJC Metab. Endocr. 2016; 13: 6-11
        • Vuilleumier N.
        • Pagano S.
        • Montecucco F.
        • Querciolo A.
        • Schindler T.H.
        • Mach F.
        • et al.
        Relationship between HDL cholesterol efflux capacity, calcium coronary artery content, and antibodies against apolipoprotein A-1 in obese and healthy subjects.
        J Clin Med. 2019; 8: 1225
        • Zimetti F.
        • Freitas W.M.
        • Campos A.M.
        • Daher M.
        • Adorni M.P.
        • Bernini F.
        • et al.
        Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability, and telomere length in healthy octogenarians.
        J Lip Res. 2018; 59: 714-721
        • Yeboah J.
        • McClelland R.L.
        • Polonsky T.S.
        • et al.
        Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.
        JAMA. 2012; 308: 788-795
        • Criqui M.H.
        • Denenberg J.O.
        • Ix J.H.
        • McClelland R.L.
        • Wassel C.L.
        • Rifkin D.E.
        • et al.
        Calcium density of coronary artery plaque and risk of incident cardiovascular events.
        JAMA. 2014; 311: 271-278
        • Yvan-Charvet L.
        • Kling J.
        • Pagler T.
        • Li H.
        • Hubbard B.
        • et al.
        Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
        Arterioscler Thromb Vasc Biol. 2010; 30: 1430-1438
        • Carr J.J.
        • Nelson J.C.
        • Wong N.D.
        • McNitt-Gray M.
        • Arad Y.
        • Jacobs Jr, D.R.
        • et al.
        Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of multi-ethnic study of atherosclerosis (MESA) and coronary artery risk development in young adults (CARDIA) study.
        Radiology. 2005; 234: 35-43
        • Nelson J.C.
        • Kronmal R.A.
        • Carr J.J.
        • McNitt-Gray M.F.
        • Wong N.D.
        • Loria C.M.
        • Goldin J.G.
        • Williams O.D.
        • Detrano R.
        Measuring coronary calcium on CT images adjusted for attenuation differences.
        Radiology. 2005; 235: 403-414
        • Favari E.
        • Ronda N.
        • Adorni M.P.
        • Zimetti F.
        • Salvi P.
        • Manfredini M.
        • Bernini F.
        • Borghi C.
        • Cicero A.F.G.
        ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects.
        J. Lipid Res. 2013; 54: 238-243
        • Vign G.B.
        • Satta E.
        • Bernini F.
        • Boarini S.
        • Bosi C.
        • Giusto L.
        • Pinotti E.
        • Tarugi P.
        • Vanini A.
        • Volpato S.
        • et al.
        Flow-mediated dilation, carotid wall thickness and HDL function in subjects with hyperalphalipoproteinemia.
        Nutr Metab Cardiovasc Dis. 2014; 24: 777-783
        • Soria-Florido M.T.
        • Castañer O.
        • Lassale C.
        • Estruch R.
        • Salas-Salvadó J.
        • Martínez-González M.Á.
        • et al.
        Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk: a nested case-control study.
        Circulation. 2020; 141: 444-453
        • Catapano A.L.
        • Pirillo A.
        • Bonacina F.
        • Norata G.D.
        HDL in innate and adaptive immunity.
        Cardiovasc Res. 2014; 103: 372-383
        • Westerterp M.
        • Gautier E.L.
        • Ganda A.
        • Molusky M.M.
        • Wang W.
        • Fotakis P.
        • Randolph G.J.
        • D'Agati V.D.
        • Yvan-charvet L.
        • Laurent-Tall A.R.
        Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity.
        Cell Metab. 2017; 25: 1294-1304
        • Khera A.V.
        • Demier O.V.
        • Adelman S.J.
        • Collins H.L.
        • Glynn R.J.
        • Ridker P.M.
        • Rader D.J.
        • Mora S.
        Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
        Circulation. 2017; 135: 2494-2504
        • Ronsein G.E.
        • Hutchins P.M.
        • Isquith D.
        • Vaisar T.
        • Zhao X.
        • Heinecke J.W.
        Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects.
        Arterioscler Thromb Vasc Biol. 2016; 36: 404-411